<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(9)</volume><submitter>Wang R</submitter><pubmed_abstract>&lt;b>Rationale:&lt;/b> Early discovery, accurate diagnosis, and staging of lung cancer is essential for patients to receive appropriate treatment. PET/CT has become increasingly recognized as a valuable imaging modality for these patients, but there remains room for improvement in PET tracers. We aimed to evaluate the feasibility of using [&lt;sup>68&lt;/sup>Ga]Ga-FAPI-RGD, a dual-targeting heterodimeric PET tracer that recognizes both fibroblast activation protein (FAP) and integrin α&lt;sub>v&lt;/sub>β&lt;sub>3&lt;/sub> for detecting lung neoplasms, by comparing it with [&lt;sup>18&lt;/sup>F]FDG and single-targeting tracers [&lt;sup>68&lt;/sup>Ga]Ga-RGD and [&lt;sup>68&lt;/sup>Ga]Ga-FAPI. &lt;b>Methods:&lt;/b> This was a pilot exploratory study of patients with suspected lung malignancies. All 51 participants underwent [&lt;sup>68&lt;/sup></pubmed_abstract><journal>Theranostics</journal><pagination>2979-2992</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10240811</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Dual targeting PET tracer [&lt;sup>68&lt;/sup>Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study.</pubmed_title><pmcid>PMC10240811</pmcid><pubmed_authors>Peng X</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Wang R</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Jakobsson V</pubmed_authors><pubmed_authors>Zhao T</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Liang N</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Xue J</pubmed_authors><pubmed_authors>Wang J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Dual targeting PET tracer [&lt;sup>68&lt;/sup>Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study.</name><description>&lt;b>Rationale:&lt;/b> Early discovery, accurate diagnosis, and staging of lung cancer is essential for patients to receive appropriate treatment. PET/CT has become increasingly recognized as a valuable imaging modality for these patients, but there remains room for improvement in PET tracers. We aimed to evaluate the feasibility of using [&lt;sup>68&lt;/sup>Ga]Ga-FAPI-RGD, a dual-targeting heterodimeric PET tracer that recognizes both fibroblast activation protein (FAP) and integrin α&lt;sub>v&lt;/sub>β&lt;sub>3&lt;/sub> for detecting lung neoplasms, by comparing it with [&lt;sup>18&lt;/sup>F]FDG and single-targeting tracers [&lt;sup>68&lt;/sup>Ga]Ga-RGD and [&lt;sup>68&lt;/sup>Ga]Ga-FAPI. &lt;b>Methods:&lt;/b> This was a pilot exploratory study of patients with suspected lung malignancies. All 51 participants underwent [&lt;sup>68&lt;/sup></description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-07-14T21:11:19.116Z</modification><creation>2025-04-06T14:08:39.702Z</creation></dates><accession>S-EPMC10240811</accession><cross_references><pubmed>37284441</pubmed><doi>10.7150/thno.86007</doi></cross_references></HashMap>